Andreas Busch
Corporate Officer/Principal bei ABSCI CORPORATION
Vermögen: 1 Mio $ am 31.03.2024
Profil
Andreas Eugen Busch is currently the Chief Innovation Officer at Absci Corp.
He previously served as the Vice Chairman-Supervisory Board at Centogene NV from 2022 to 2023.
Prior to that, he was the Chief Scientific Officer & Executive VP at Shire Plc from 2018 to 2019.
Andreas also held the position of Executive VP & Head-Global Drug Discovery at Bayer HealthCare AG.
He has a background in academia, having worked as a Professor at Johann Wolfgang Goethe-Universität Frankfurt am Main.
Andreas has extensive experience in the pharmaceutical industry, including roles such as Head-Global Drug Discovery at Bayer Pharma AG from 2006 to 2017 and Head-Cardiovascular Research at Aventis Pharma AG from 1999 to 2005.
He also served as the Global Head-Cardiovascular Research at Sanofi-Aventis Groupe SA from 1997 to 2005.
Additionally, Andreas has been a Member-Supervisory Board at Max-Delbrück-Centrum für Molekulare Medizin (MDC).
He holds a doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main, which he obtained in 1989.
Currently, Dr. Busch is the Chief Scientific Officer at Cyclerion Therapeutics, Inc.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ABSCI CORPORATION
0,23% | 01.02.2024 | 258 125 ( 0,23% ) | 1 Mio $ | 31.03.2024 |
Aktive Positionen von Andreas Busch
| Unternehmen | Position | Beginn |
|---|---|---|
| ABSCI CORPORATION | Corporate Officer/Principal | 04.10.2022 |
Ehemalige bekannte Positionen von Andreas Busch
| Unternehmen | Position | Ende |
|---|---|---|
| CENTOGENE N.V. | Director/Board Member | 12.12.2023 |
| CYCLERION THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 30.09.2022 |
| SHIRE | Chief Tech/Sci/R&D Officer | 01.03.2019 |
Bayer Pharma AG
 Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany. | Corporate Officer/Principal | 01.12.2017 |
| Aventis Pharma AG | Corporate Officer/Principal | 01.01.2005 |
Ausbildung von Andreas Busch
| Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ABSCI CORPORATION | Health Technology |
| CYCLERION THERAPEUTICS, INC. | Health Technology |
| CENTOGENE N.V. | Commercial Services |
| Private Unternehmen | 7 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Bayer HealthCare AG
 Bayer HealthCare AG Pharmaceuticals: MajorHealth Technology Bayer HealthCare AG provides healthcare, agriculture, plastics and chemical products. It is an independent company comprising five divisions: Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. The company covers the fields of animal health, genetically produced medicines, over the counter products, diagnostic products and prescription drugs. The company is headquartered in Leverkusen, Germany. | Health Technology |
Bayer Pharma AG
Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany. | Health Technology |
| Aventis Pharma AG | |
| Hoechst Marion Roussel, Inc. | |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | Commercial Services |
Sanofi-Aventis Groupe SA
 Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Sanofi-Aventis Groupe SA operates as a holding company, with interest in the manufacture and distribution of pharmaceutical products. The company was founded on December 19, 1995 and is headquartered in Paris, France. | Finance |
